Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kenneth Knowles

Nephrology Philadelphia, PA Doctor of Osteopathy

NPI 1811958564 CMS profile 82394

4453 Castor Ave, Suite B, Philadelphia, PA 19124

Open in the dashboard

General payments

$8,499

297 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kenneth Knowles of Philadelphia, PA is reported in the CMS Open Payments database as having received $8,499 across 297 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Nephrology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $996 36
2024 General $1,036 33
2023 General $1,244 33
2022 General $1,627 59
2021 General $1,247 44
2020 General $996 38
2019 General $1,352 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kenneth Knowles
  • Nephrology median
  • Middle half of Nephrology
  • National median

In program year 2025, general payments to Kenneth Knowles were reported at $996. Among 8,186 Nephrology profiles paid that year, the median was $310 and the middle half received between $104 and $880.

Show as a table
Year Kenneth Knowles Nephrology median Middle half National median
2019 $1,352 $236 $90–$588 $163
2020 $996 $135 $46–$364 $114
2021 $1,247 $202 $67–$551 $132
2022 $1,627 $242 $77–$695 $149
2023 $1,244 $254 $84–$766 $160
2024 $1,036 $300 $99–$852 $164
2025 $996 $310 $104–$880 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,571 33 payments
  2. Relypsa, Inc. $1,350 59 payments
  3. Amgen Inc. $630 29 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $487 18 payments
  5. Novartis Pharmaceuticals Corporation $471 15 payments
  6. Aurinia Pharma U.S., Inc. $391 11 payments
  7. Fresenius USA Marketing, Inc. $376 19 payments
  8. Otsuka America Pharmaceutical, Inc. $343 20 payments
  9. Alexion Pharmaceuticals, Inc. $294 5 payments
  10. Retrophin, Inc. $277 7 payments
  11. Other $2,310 81 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,499 297 payments
Products named General payments · program years 2019–2025
  1. LOKELMA $1,054 25 payments
  2. Veltassa Hyperkalemia $856 38 payments
  3. Kerendia $487 18 payments
  4. Parsabiv $440 19 payments
  5. Veltassa Hyperkalemia $430 19 payments
  6. LUPKYNIS $391 11 payments
  7. Velphoro $376 19 payments
  8. FARXIGA $292 6 payments
  9. ACTHAR $262 10 payments
  10. Vanrafia $239 10 payments
  11. Other $3,536 133 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$59,157

Medicare's payments for the services billed

Medicare patients

148

Average age 66

Services billed

529

65 women, 83 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 75%
Heart failure 66%
Ischemic heart disease 66%
Diabetes 64%
Depression 44%
Arthritis 43%
Atrial fibrillation 36%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DALVANCE
  • AbbVie, Inc. $125
$125 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $105
$105 — —
TARPEYO
  • CALLIDITAS THERAPEUTICS US INC. $105
$105 — —
PURIFIED CORTROPHIN GEL
  • ANI Pharmaceuticals, Inc. $76
$76 — —
Veltassa
  • Relypsa, Inc. $56
$56 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

297 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nephrology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record